104 related articles for article (PubMed ID: 27717655)
1. [Raynaud's phenomenon secondary to anti-glaucoma eye drops].
Bugarín-González R; Portela-Romero M; Maceira-Rozas MC; López-Vázquez P; Bugarín-Diz C
Semergen; 2017; 43(4):e49-e50. PubMed ID: 27717655
[No Abstract] [Full Text] [Related]
2. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.
Renieri G; Führer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
J Ocul Pharmacol Ther; 2010 Dec; 26(6):597-603. PubMed ID: 20977366
[TBL] [Abstract][Full Text] [Related]
3. Accelerated idioventricular rhythm associated to ophthalmic timolol/dorzolamide solution.
Attanasio A; Baglio S; Quatrana M; Bartorelli L
Int J Cardiol; 2004 Jun; 95(2-3):343-5. PubMed ID: 15193844
[No Abstract] [Full Text] [Related]
4. Fixed topical combinations in glaucomatous patients and ocular discomfort.
Nebbioso M; Evangelista M; Librando A; Di Blasio D; Pescosolido N
Expert Opin Pharmacother; 2012 Sep; 13(13):1829-35. PubMed ID: 22770575
[TBL] [Abstract][Full Text] [Related]
5. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
6. Skin eruption and thrombocytopaenia in a woman with glaucoma: a case report.
Santos VM; Castro RA; Lima CC; Moraes MB; Sugai TA
West Indian Med J; 2010 Jan; 59(1):102-5. PubMed ID: 20931926
[TBL] [Abstract][Full Text] [Related]
7. [Azarga, a new and useful fixed combination in glaucoma treatment].
Călugăru M; Călugăru D
Oftalmologia; 2011; 55(3):38-46. PubMed ID: 22428291
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of dorzolamide/timolol and latanoprost/timolol fixed combinations upon intraocular pressure and progression of visual field damage in primary open-angle glaucoma.
Pajic B; Pajic-Eggspuehler B; Häfliger IO
Curr Med Res Opin; 2010 Sep; 26(9):2213-9. PubMed ID: 20673200
[TBL] [Abstract][Full Text] [Related]
9. Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops.
Mullins RJ; Lones R; Dutta B
Australas J Dermatol; 2004 May; 45(2):151-2. PubMed ID: 15068470
[No Abstract] [Full Text] [Related]
10. Allergic contact dermatitis from timolol and dorzolamide eye drops.
Kalavala M; Statham BN
Contact Dermatitis; 2006 Jun; 54(6):345. PubMed ID: 16787459
[No Abstract] [Full Text] [Related]
11. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study.
Martínez A; Sánchez M
Clin Ther; 2008 Jun; 30(6):1120-34. PubMed ID: 18640468
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Sezgin Akçay Bİ; Güney E; Bozkurt KT; Unlü C; Akçali G
J Ocul Pharmacol Ther; 2013 Dec; 29(10):882-6. PubMed ID: 24180628
[TBL] [Abstract][Full Text] [Related]
13. Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy.
Sonty S; Henry JC; Sharpe ED; Weiss MJ; Stewart JA; Nelson LA; Stewart WC
Acta Ophthalmol; 2008 Jun; 86(4):419-23. PubMed ID: 18039347
[TBL] [Abstract][Full Text] [Related]
14. The effect of nebulized dorzolamide/timolol fixed combination mist versus drops on retrobulbar blood flow and intraocular pressure in glaucoma patients.
Janulevičienė I; Šiaudvytytė L; Baršauskaitė R; Dilienė V; Kuzmienė L; Siesky B; Harris A
Medicina (Kaunas); 2013; 49(7):310-4. PubMed ID: 24375242
[TBL] [Abstract][Full Text] [Related]
15. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy.
Konstas AG; Mikropoulos D; Dimopoulos AT; Moumtzis G; Nelson LA; Stewart WC
Br J Ophthalmol; 2008 Nov; 92(11):1498-502. PubMed ID: 18703549
[TBL] [Abstract][Full Text] [Related]
16. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
17. [Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma].
Schmidt KG; von Rückmann A; Becker R; Pillunat LE
Klin Monbl Augenheilkd; 1999 Dec; 215(6):361-6. PubMed ID: 10637801
[TBL] [Abstract][Full Text] [Related]
18. Toxic epidermal necrolysis secondary to timolol, dorzolamide, and latanoprost eyedrops.
Flórez A; Rosón E; Conde A; González B; García-Doval I; de la Torre C; Cruces M
J Am Acad Dermatol; 2005 Nov; 53(5):909-11. PubMed ID: 16243161
[No Abstract] [Full Text] [Related]
19. Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients.
Sakai H; Shinjyo S; Nakamura Y; Nakamura Y; Ishikawa S; Sawaguchi S
J Ocul Pharmacol Ther; 2005 Dec; 21(6):483-9. PubMed ID: 16386090
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.
Baiza-Durán LM; Alvarez-Delgado J; Contreras-Rubio AY; Medrano-Palafox J; De Luca-Brown A; Casab-Rueda H; Cortés-Gastélum MA; Garcidueñas-Mejía MJ; Gómez-Bastar P; Gil-Carrasco F; Hartleben-Matkin C; Jiménez-Román J; Moreno-Marín ML; Paczka-Zapata JA; Velasco-Gallegos G; Vergara-Sinta M
Ann Ophthalmol (Skokie); 2009; 41(3-4):174-8. PubMed ID: 20214051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
